CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 121 enrolled
Drug / intervention
Docetaxel +3 moredrug
Likely dose
Docetaxel 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00514540
NCT00514540Phase 2Completed
CompareCT.gov

Phase II Study of Carboplatin Plus Docetaxel (Taxotere) in Patients With Anaplastic Prostate Carcinoma

M.D. Anderson Cancer Center·interventional·Posted Aug 10, 2007·Updated Sep 1, 2020

In Brief

A Phase 2 clinical trial evaluating Docetaxel, Carboplatin, and 2 other interventions for Prostate Cancer. Completed, enrolled 121 participants across 2 sites.

Detailed Summary

The goal of this clinical research study is to learn about how effective 2 chemotherapy drugs carboplatin (Paraplatin) plus docetaxel (Taxotere) in the treatment of patients with anaplastic prostate cancer. Patients who continue to have advanced disease will be switched to etoposide (VePesid) plus cisplatin (Platinol-AQ) to study how effective this second line of chemotherapy is in the treatment of patients iwth anaplastic prostate cancer. The side effects, characteristics of patients who respond, and overall survival will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 10, 2007
Enrollment StartMay 1, 2006
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 18.9 years ago

Interventions

Docetaxeldrug

75 mg/m\^2 IV over 60 Minutes on Day 1 of 21 day cycle.

Carboplatindrug

AUC = 5 IV Over 30 Minutes On Day 1 of 21 day cycle.

Etoposidedrug

120 mg/m\^2 daily for 3 days of 21 day cycle.

Cisplatindrug

25 mg/m\^2 for 3 days of 21 day cycle.